Larimar Therapeutics, Inc.

NASDAQ:LRMR

3.78 (USD) • At close December 24, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q32015 Q22015 Q12014 Q32014 Q2
Revenue 00000000000000000000000000000000000000000
Cost of Revenue 0.0740.0870.080.0810.0690.0490.0540.0320.0770.0810.0820.0880.0880.0770.07300000000000000000000000000
Gross Profit -0.074-0.087-0.08-0.081-0.069-0.049-0.054-0.032-0.077-0.081-0.082-0.088-0.088-0.077-0.07300000000000000000000000000
Gross Profit Ratio 00000000000000000000000000000000000000000
Reseach & Development Expenses 13.91919.59512.85910.5676.5855.8754.5627.2185.5825.6445.8066.29214.0289.1028.97410.5636.9198.9075.0075.4068.0343.1280.00411.45711.8312.20912.43310.9119.72310.5289.6777.27510.00110.16312.49717.70614.17112.52610.21512.0764.695
General & Administrative Expenses 4.3454.9173.7953.5143.7543.7453.0753.2212.9313.0433.0812.7942.7023.4413.1323.8323.4162.4921.6670.7520.5940.5760.0013.2343.3393.3513.2692.4473.1173.0083.5883.24.834.8995.365.545.5465.0843.0252.2851.291
Selling & Marketing Expenses 00.1000000000000000000000000000000000000000
SG&A 4.3454.9173.7953.5143.7543.7453.0753.2212.9313.0433.0812.7942.7023.4413.1323.8323.4162.4921.6670.7520.5940.5760.0013.2343.3393.3513.2692.4473.1173.0083.5883.24.834.8995.365.545.5465.0843.0252.2851.291
Other Expenses 02.9722.081.1691.2751.2541.1111.0140.1930.02-0.056-0.048-0.075-0.0660.0180.1920.0610.06905.5534.01900000000000000000000
Operating Expenses 18.26424.51216.65414.08110.3399.627.63710.4398.5138.6878.8879.08616.7312.54312.10614.39510.33511.3996.6746.1588.6283.7040.00514.69115.16915.5615.70213.35812.8413.53613.26510.47514.83115.06217.85723.24619.71717.6113.2414.3615.986
Operating Income -18.264-24.599-16.734-14.162-10.339-9.62-7.637-10.439-8.513-8.687-8.887-9.086-16.73-12.543-12.106-14.395-10.335-11.399-6.674-6.158-8.628-3.704-0.005-14.691-15.169-15.56-15.702-13.358-12.84-13.536-13.265-10.475-14.831-15.062-17.857-23.246-19.717-17.61-13.24-14.361-5.986
Operating Income Ratio 00000000000000000000000000000000000000000
Total Other Income Expenses Net 2.7652.9722.081.1691.2751.2541.1111.0140.1930.02-0.056-0.048-0.075-0.0660.0180.1920.0610.06900.08200-8.3880.1210.102-0.215-0.2540.2730.2550.1890.2540.0360.1560.0340.1210.072-0.167-0.146-0.232-0.328-0.457
Income Before Tax -15.499-21.627-14.654-12.993-9.064-8.366-6.526-9.425-8.32-8.667-8.943-9.134-16.805-12.609-12.088-14.203-10.274-11.33-6.674-6.076-8.628-3.704-0.005-14.57-15.067-15.775-15.956-13.085-12.585-13.347-13.011-10.439-14.675-15.028-17.736-23.174-19.884-17.756-13.472-14.689-6.443
Income Before Tax Ratio 00000000000000000000000000000000000000000
Income Tax Expense 000.0370.037-0.076-0.046-1.111-1.014-0.193-0.020.056-0.088000-0.05-0.05-0.032-0.035-1.175-4.286-8.4820.33000000000000000000
Net Income -15.499-21.627-14.654-12.993-9.064-8.366-5.415-8.411-8.127-8.647-8.999-9.134-16.805-12.609-12.088-14.203-10.274-11.33-6.674-6.076-8.628-3.704-0.005-14.57-15.067-15.775-15.956-13.085-12.585-13.347-13.011-10.439-14.675-15.028-17.736-23.174-19.884-17.756-13.472-14.689-6.443
Net Income Ratio 00000000000000000000000000000000000000000
EPS -0.24-0.34-0.27-0.3-0.21-0.19-0.12-0.35-0.37-0.47-0.49-0.5-0.92-0.79-0.76-0.89-0.64-1.21-0.72-0.66-0.94-0.4-0.002-4.52-4.11-5.72-5.79-4.77-4.58-4.87-4.76-3.82-5.37-5.51-6.51-8.66-7.33-6.57-5.26-6.47-2.84
EPS Diluted -0.24-0.34-0.27-0.3-0.21-0.19-0.12-0.35-0.37-0.47-0.49-0.5-0.92-0.79-0.76-0.89-0.64-1.21-0.72-0.66-0.94-0.4-0.002-4.52-4.11-5.72-5.79-4.77-4.58-4.87-4.76-3.82-5.37-5.51-6.51-8.66-7.33-6.57-5.26-6.47-2.84
EBITDA -18.264-24.512-16.654-14.081-10.263-9.544-7.559-10.361-8.436-8.606-8.805-8.998-16.642-12.466-12.033-14.346-10.285-11.367-6.651-6.138-8.608-3.685-4.705-14.691-15.169-15.56-15.702-13.358-12.84-13.536-13.265-10.475-14.831-15.062-17.857-23.246-19.717-17.61-13.24-14.361-5.986
EBITDA Ratio 00000000000000000000000000000000000000000